Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novacea acquires license to anticancer drug
As part of the agreement, Novacea will gain the rights for the worldwide development and commercialization of AQ4N. KuDOS said that it anticipates the completion of patient recruitment
As part of the agreement, Novacea will gain the rights for the worldwide development and commercialization of AQ4N. KuDOS said that it anticipates the completion of patient recruitment
The company also commented that the database for the North American phase III clinical trial for Alzhemed has been locked, which means that Neurochem has finished collecting data
Antisoma believes the deal will provide it with extra resources it can use to further expand its pipeline and to exploit the value in its present portfolio. The
Results from the study, show that over five years there is one extra case of ovarian cancer in every 2,500 women who take HRT. And for every 3,300
Vical has provided Vaxfectin to researchers for several years, and data have been published showing evidence of increased immunogenicity and protective efficacy of DNA vaccines against diseases including
The anti-IgE immunotherapy, RP01, is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. The primary
PDX has already been awarded orphan drug designation by the FDA for the treatment of patients with T-cell lymphoma in July 2006. The orphan medicinal product designation is
The compound, TRA-SCH 530348, is being evaluated to determine whether it has the potential to provide clinical benefit without the additional bleeding liabilities often found in current therapies.
Scientists from the University of Texas at Austin developed the new antibody-production approach to improve upon processes used previously to identify new drugs. Drug companies have used the
This is the second program between the two companies under an agreement signed in August 2006. In this new collaboration, BioFocus DPI will perform medicinal chemistry, computational chemistry